A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69437
- Hopital Edouard Herriot - CHU Lyon
-
Marseille, France, 13385
- Aphm Hopital Timone
-
-
-
-
-
Bonn, Germany, 53127
- Universitatsklinikum Bonn
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Academisch Medisch Centrum Universiteit van Amsterdam
-
-
-
-
-
Río Piedras, Puerto Rico, 00 935
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Madrid, Spain, 8036
- Hosp. Clinic I Provincial de Barcelona
-
Pamplona, Spain, 31008
- Clinica Univ. de Navarra
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Genetic diagnosis of classical familial adenomatous polyposis (FAP) (adenomatous polyposis coli [APC] germline mutation or obligate carrier) with disease involvement of the colorectum
- At least 6 polyps greater than or equal to (>=) 2 millimeters (mm) in diameter in the rectum or colon
- A female participant of childbearing potential must have a negative highly sensitive pregnancy test at screening and within 72 hours prior to the first dose of study drug and must agree to further pregnancy tests during the study
- A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study drug
- Must sign an informed consent form (ICF) indicating he or she understands the purpose of the study and procedures required for the study and is willing to participate in the study. Consent is to be obtained prior to the initiation of any study-related tests or procedures that are not part of standard of care for the participant's disease
Exclusion Criteria:
- Use of non-steroidal anti-inflammatory drugs (example, aspirin, ibuprofen) exceeding 5 days per month or exceeding the nonprescription dose, unless the participant completes a 4-week washout period prior to the first dose of study drug
- Treatment with other FAP-directed drug therapy (including sulindac or celecoxib), unless completes a 4-week washout period prior to the first dose of study drug
- History of human immunodeficiency virus (HIV)
- History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof
- A history of, or ongoing, chronic or recurrent infectious disease including latent or active tuberculosis (TB)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: JNJ-64251330
Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
|
JNJ-64251330 tablets will be administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage Change from Baseline in Colorectal Polyp Burden for all Polyps at Week 24
Time Frame: Baseline and Week 24
|
Percentage change from baseline in colorectal polyp burden for all polyps (the sum of the polyp diameters) at Week 24 will be reported.
|
Baseline and Week 24
|
|
Percentage Change from Baseline in Colorectal Polyp Burden for Polyps >=2 mm at Week 24
Time Frame: Baseline and Week 24
|
Percentage change from baseline in colorectal polyp burden (sum of the polyp diameters) for polyps greater than or equal to (>=) 2 millimeters (mm) at Week 24 will be reported.
|
Baseline and Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage Change in Number of Colon Polyps
Time Frame: Baseline and Week 24
|
Percentage change in number of colon polyps will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Number of Rectal Polyps
Time Frame: Baseline and Week 24
|
Percentage change in number of rectal polyps will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Number of J-pouch Polyps
Time Frame: Baseline and Week 24
|
Percentage change in number of J-pouch polyps (for participants with an ileal pouch-anal anastomosis [IPAA]) will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Number of Duodenal Polyps
Time Frame: Baseline and Week 24
|
Percentage change in number of duodenal polyps will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Colon Polyp Burden for all Polyps, Polyps >=2 mm and Polyps >=5 mm
Time Frame: Baseline and Week 24
|
Percentage change in colon polyp burden for all polyps, polyps >=2 mm and polyps >=5 mm will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Rectal Polyp Burden for all Polyps, Polyps >=2 mm and Polyps >=5 mm
Time Frame: Baseline and Week 24
|
Percentage change in rectal polyp burden for all polyps, polyps >=2 mm and polyps >=5 mm will be reported.
|
Baseline and Week 24
|
|
Percentage Change in J-Pouch Polyp Burden for all Polyps, Polyps >=2 mm and Polyps >=5 mm
Time Frame: Baseline and Week 24
|
Percentage change in J-Pouch polyp (for participants with an IPAA) burden for all polyps, polyps >=2 mm and polyps >=5 mm will be reported.
|
Baseline and Week 24
|
|
Percentage Change in Duodenal Polyp Burden for all Polyps, Polyps >=2 mm and Polyps >=5 mm
Time Frame: Baseline and Week 24
|
Percentage change in duodenal polyp burden for all polyps, polyps >=2 mm and polyps >=5 mm will be reported.
|
Baseline and Week 24
|
|
Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Polyposis Stage (with and Without Colon)
Time Frame: Baseline and Week 24
|
Change in InSiGHT stage will be reported.
Various stages are defined as: a) With Colon: Stage 0: 0-10 polyps,all less than [<]5mm); Stage 1: 20-200 polyps,most <5 mm, none, >1 centimeters[cm]; Stage 2: 200-500 polyps,<10 that are >1 cm; Stage 3: 500-1000 polyps or any number if there are 10-50 that are >1 cm and amenable to complete polypectomy; Stage 4: >1000 polyps and/or any polyps grown to confluence and not amenable to simple polypectomy, any invasive cancer; b) Without Colon: Stage 0: 0 -10 polyps, all <5 mm; Stage 1: 10-25 polyps most <5 mm, none >1 cm; Stage 2: 10-25 polyps, any >1 amenable to complete removal; Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high-grade dysplasia (HGD), even if completely excised; Stage 4: >25 polyps not amenable complete removal, or any incompletely excised sessile polyp showing HGD; any invasive cancer.
|
Baseline and Week 24
|
|
Change in Spigelman Stage Score
Time Frame: Baseline and Week 24
|
Change in Spigelman stage score will be reported.
Spigelman classification system measures risk of developing duodenal cancer in familial adenomatous polyposis (FAP).
It has been classified in following stages- Stage 0 (0 points); Stage 1 (1-4 points); Stage 2 (5-6 points); Stage 3 (7-8 points); and Stage 4 (9-12 points).
The total score ranges from 0 to 12.
The higher the score, the more severe or advanced the FAP disease in the duodenum.
|
Baseline and Week 24
|
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 32 weeks
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
|
Up to 32 weeks
|
|
Number of Participants with AEs by Severity
Time Frame: Up to 32 weeks
|
Number of participants with AEs by severity will be reported.
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).
Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to AE.
|
Up to 32 weeks
|
|
Plasma Concentration of JNJ-64251330 Over Time
Time Frame: Up to Week 24
|
Plasma samples will be analyzed to determine plasma concentrations of JNJ-64251330 using a validated specific, and sensitive liquid chromatography coupled to tandem mass spectrometry detection (LC-MS/MS).
|
Up to Week 24
|
|
Tissue Concentration of JNJ-64251330 Over Time
Time Frame: Up to Week 24
|
Tissue biopsy samples will be analyzed to determine tissue concentrations of JNJ-64251330 using a validated specific, and sensitive LC-MS/MS.
|
Up to Week 24
|
|
Levels of JAK/STAT Pathway Signaling Effector Proteins including pSTAT-3 Relative to Baseline Levels in Colorectal Polyps
Time Frame: Up to Week 24
|
Levels of Pan-janus kinase (JAK)/ signal transducer and activator of transcription (STAT) pathway signaling effector proteins including phosphorylated (p) STAT-3 relative to baseline levels in colorectal polyps will be reported.
Polyp and tissue samples will be collected to monitor for changes to the JAK-STAT pathway.
|
Up to Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Syndromes, Hereditary
- Adenomatous Polyps
- Adenoma
- Intestinal Polyposis
- Nasopharyngeal Neoplasms
- Colorectal Neoplasms
- Adenomatous Polyposis Coli
Other Study ID Numbers
Other Study ID Numbers
- CR109012
- 2021-001068-16 (EudraCT Number)
- 64251330COR1001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.